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Mathematical Modeling of HIV Dynamics
After Antiretroviral Therapy Initiation:
A Clinical Research Study
Pablo S. Rivadeneira,1,2 Claude H. Moog,2 Guy-Bart Stan,3 Vicente Costanza,1 Ce´cile Brunet,4,5
Francois Raffi,4,5 Virginie Ferre´,4,5 Marie-Jose´ Mhawej,2 Federico Biafore,6
Djomangan A. Ouattara,2 Damien Ernst,7 Raphael Fonteneau,7 and Xiaohua Xia8
Editor: Immunological failure is identified from the es-timation of certain parameters of a mathematical model
of HIV infection dynamics. This identification is supported
by clinical research results from an original clinical trial.
Standard clinical data were collected from infected patients
starting highly active antiretroviral therapy (HAART) after
just 1 month of therapy initiation and were used to carry out
the model identification. The early diagnosis is shown to be
consistent with patient monitoring after 6 months.
Early Diagnosis of Immunological Failure
Clinical research shows that parameter identification
methods constitute an efficient means to characterize critical
patients (patients under clinical failure) just 1 month after
initiation of a new therapy.1–3 A clinical trial has been set up
for the first time to show that mathematical systems analysis
is able to help clinicians in the early diagnosis of immuno-
logical failure and in making decisions for treating HIV-
infected patients.3
The immune potential is given by the maximal level of
CD4 + T cells that can be reached if a 100% efficient treat-
ment is administered. This maximal level is obtained by
setting the virus load (V) equal to 0 in the first equation of
model (2) in reference 4 and computing its equilibrium point
(Dmax) as Dmax¼ sd, where healthy CD4 + cells (T) are pro-
duced from the thymus at a constant rate s and die with a half-
life equal to 1d. Patients with a normal thymus function must
have a Dmax > 200 CD4/mm3.1,4 However, in practice, it is
desirable to reach the equilibrium Dmax within a reasonable
time (around 6 months in general). Thus, a more restrictive
evaluation of the status of the immune system is provided by
the time required to reach the critical threshold of 200 CD4/
mm3, denoted as t200 (in days). For patients who are not in
immunological failure, t200 is lower than 6 months. More
generally, tD denotes the time required to reach the level D of
CD4 T cell count in case of 100% efficient therapy. tD is
computed as follows (see also reference 3 for more details):














where T(0) is the initial healthy CD4 + T cell concentration.
Immunological failure is also related to a dysfunctional
thymus3 (characterized by small values of the parameter s),
which is unable to produce a sufficient amount of healthy
CD4 + T cells. However, it has also been argued that im-
munological failure is predominantly due to an important
activation-induced apoptosis phenomenon (characterized by
high values of the activation-induced apoptosis rate A, which
appears in the term -ATT* of the first line of Eq. (2) in
reference 4), where T* is the infected cell concentration and s
(CD4mm - 3/day) and A (CD4 - 1 mm - 6/day) are parameters
of the model.
Summarizing, patients are declared to be critical if they
belong to one of the following groups:
 A low value of the parameter s (s £ 3) and a high value
of the parameter A (A> 10- 3), or
 Dmax < 200 CD4/mm3, or
 Dmax ‡ 200 CD4/mm3, but t200 > 6 months.
Since available measurements typically contain the total
(uninfected and infected) CD4 + T cell concentration (T), the
concentration of free virions (V), and the concentration of
CTL cells (TCTL), the output measurements [for model (2) in
reference 4] are y1 = T +T*, y2 =V, and y3 =TCTL. According
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to identifiability theory results presented in reference 5,
model (2) in reference 4 is algebraically identifiable from
output measurements given by (y1, y2, y3). The computation
of the criterion of identifiability5 shows that at least 15
measurements are needed (5 for y1, 5 for y2, and 5 for y3), i.e.,
five blood samples are required to compute all parameters of
the model. Sensitivity analysis of the parameters against
outputs5 suggests that the first weeks of treatment reveal
muchmore information than other intervals. Therefore, blood
measurements were taken during the first 3 weeks after the
initiation of treatment. After that, several blood samples were
taken to control the prediction of the model and the patient’s
evolution (see Table 2).
The identification method used in this study was developed
and implemented in a software package available online
from reference 2. It was based on the Monte Carlo approach,
combined with a simplex optimization method. To avoid
local optima, random initial conditions were drawn from
uniform distributions in the admissible parameter space and
corresponding estimates were computed. Using the median
and interquartile range of the estimates’ distributions, reliable
estimations and confidence intervals of the parameters were
deduced. For model (2) in reference 4 (with g1 = 0), a num-
ber of 1,000 randomization was sufficient to obtain stable
and robust results.4 The calibration of the algorithm was as
follows:
 Life-time parameters were set to constant values iden-
tical to typical values published in reference 4. For
instance: d = 0.01 d - 1.
 Based on the biological characteristics of the infection, the
other parameters were constrained to belong to the fol-
lowing intervals: s 2 [1E 5:20] and A 2 [1E 20:1].
 The uniform distributions U used for the initial con-
ditions were: UA 2 [1E 10:05] and Us 2 [1E 5:10].
Results of the identification of the parameters sjA= 0, and
Ajs = 63 are shown in Table 1 for each patient in the EDV05
trial.2 The primary data collected during the trial are shown in
Table 2.
Discussion
The last column in Table 1 displays the theoretical time
t200 predicted to be necessary to recover a CD4 level above
200 CD4/mm3. This theoretical time t200 was computed from
Eq. (1) using parameter identification, based only on the
samples from the first 3 weeks after initiation of therapy.
According to this theoretical time t200, four patients (in bold
in Table 1) are predicted to be in immunological failure since
they will not be able to recover the desired CD4 level of 200
CD4/mm3 within 6 months. The 11 remaining patients are
predicted to recover within 6 months, and among those, 10
patients are even predicted to recover the desired CD4 level
within 3 months.
Based on the identification of parameters s or A only, six
patients are declared to be critical: they are those for whom
t200 > 3 months. Patient 16 (in italic in Table 1) was only 18
years old when he was enrolled in the trial. He had a very low
level of 3 CD4/mm3. This patient was very young and his
immunological system demonstrated an ability to recover
from its critical status after 6 months as is shown in Table 2.
In Table 1, t200 was predicted from Eq. (1) to lie within the 3
months range. The last column of Table 2 displays the im-
munological status of the patients after 6 months. The latter is
fully consistent with the above results. The 11 patients reaching
the level 200 CD4/mm3 within 6 months are all correctly
identified, which suggests a good sensitivity of the measure
based on the identified parameters s and A. The four patients
having a level below 200CD4/mm3 after 6months are correctly
identified as well, which again suggests a good specificity of
the measure. These latter statements deserve an exhaustive
statistical study, which is beyond the scope of this trial.
The conclusion from Table 1 is that the identification of the
parameters in model (2) in reference 4 as a tool for the early






thymus sjA = 0
Important
apoptosis
Ajs = 6 Dmax t200
01 376 8.13 1.69E-08 6.25E + 02 0
02 230 9.53 1.87E-07 8.533E + 02 0
03 185 1.77 1.54E-03 8.306E101 N
04 205 5.45 4.54E-06 3.761E + 02 0
05 383 6.76 6.81E-06 5.551E + 02 0
06 405 6.94 1.36E-06 6.644E + 02 0
07 9 3.01 1.11E-02 6.344E + 02 195.9
08 122 6.41 9.146E-06 3.727E + 02 33.9
09 118 5.36 5.05E-05 3.067E + 02 34.4
10 200 4.00 3.36E-04 3.333E + 02 3.1
11 23 2.08 8.19E-03 1.163E102 N
12 310 7.66 7.20E-06 5.610E + 02 0
13 29 2.67 1.87E-02 2.130E102 291.3
14 140 6.51 1.09E-06 4.049E + 02 25.3
15 63 2.29 8.43E-03 2.767E102 248.7
16 3 0.61 3.51E-01 8.654E + 02 166.5
The two approaches reveal the same critical patients. Half-life parameters are set to constant values, which are in accordance with typical
values published in references 1, 3, and 4. Patients in bold are in immunological failure. Patient 16 in italic recovered his immunological
status due to his young age.























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































diagnosis of immunological failure immediately after the first
month following the initiation of a new therapy is useful and
very effective. However, the peculiarities of each patient
must be taken into account by the physician to make a final
clinical decision. For future work, different avenues of
research could be explored using methods relying on math-
ematical analysis and systems and control theory, e.g., the
diagnosis of irreversible treatment failure, confirmation of
resistance, and identification of patients who are likely to be
more vulnerable to the level of adherence.
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